Leydig Cell Hyperplasia of Ovary - An Unusual Finding in Postneoadjuvant Chemotherapy Case of Primary Fallopian Tube Carcinoma

J Midlife Health. 2022 Jul-Sep;13(3):247-250. doi: 10.4103/jmh.jmh_117_22. Epub 2023 Jan 14.

Abstract

A large number of high-grade serous ovarian carcinomas originate in the fallopian tubes. Neoadjuvant chemotherapy followed by surgery may lead to a number of chemotherapy-induced changes in the ovary, which may lead to an erroneous diagnosis. We present a rare case of a 55-year-old postmenopausal woman who was clinically diagnosed with carcinoma of the right ovary; on histopathologic evaluation after neoadjuvant chemotherapy, the primary site was found to be the right fallopian tube. The right ovary showed chemotherapy-related changes along with extensive Leydig cell hyperplasia. As the presence of Leydig cell hyperplasia in this setting is an unusual finding, it may pose a diagnostic dilemma for the pathologist; so an awareness of this entity is important to avoid misdiagnosis.

Keywords: Leydig cell hyperplasia; Neoadjuvant chemotherapy; primary fallopian tube carcinoma.

Publication types

  • Case Reports